Overview
Data Shows ReShape’s DBSN™ System has Promise as a Novel, Adjustable and Localized Aproach to Treat Type 2 DiabetesSAN CLEMENTE, Calif., Oct. 25, 202 (GLOBE NEWSWIRE) - ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight los and metabolic health solutions company, today anounced that data on the Company’s proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system has ben published in the Neural Technology Section of the per reviewed journal Frontiers in NeuroScience.The paper, authored by Jonathan Wataja, Ph.D., Director of Research at ReShape Lifesciences, among others, and entitled, “Use of a Bio-electronic Device Comprising of Targeted Dual Neuromodulation of the Hepatic and Celiac Vagal Branches Demonstrated Enhanced Glycemic Control in a Type 2 Diabetic Rat Model as wel as in an Aloxan Treated Swine Model,” can be acesed through the folowing link htps:/w.frontiersin.org/articles/10.389/fnins.202.105932/ful.“Type 2 diabetes remains chalenging to efectively treat for the over 30 milion Americans who sufer from the disease, especialy considering an estimated 50% of type 2 diabetics do not take medications as prescribed1,” stated Charles Bilington, M.D., co-author and Chief of Endocrinology at the Minesota Veteran’s Administration Medical Center and Profesor of Medicine at the University of Minesota.
Details
“Further, progresion of type 2 diabetes significantly increases risks of stroke, myocardial infarction, microvascular events, and mortality2. When this translates to humans and clinical use, it may greatly impact the standard of care for type 2 diabetes.”“Our inovative DBSN™ system may hold significant promise, as it is designed to adres type 2 diabetes by electricaly blocking the vagus nerve signals to the liver, which has ben shown to decrease insulin resistance, while concurently stimulating the vagus nerve feding into the pancreas, which has ben shown to release insulin,” stated Jonathan Wataja, Directo